26 related articles for article (PubMed ID: 11119705)
21. Expression of beta-arrestins in toxic and cold thyroid nodules.
Voigt C; Holzapfel H; Paschke R
FEBS Lett; 2000 Dec; 486(3):208-12. PubMed ID: 11119705
[TBL] [Abstract][Full Text] [Related]
22. Shared sporadic and somatic thyrotropin receptor mutations display more active in vitro activities than familial thyrotropin receptor mutations.
Lueblinghoff J; Eszlinger M; Jaeschke H; Mueller S; Bircan R; Gozu H; Sancak S; Akalin S; Paschke R
Thyroid; 2011 Mar; 21(3):221-9. PubMed ID: 21190443
[TBL] [Abstract][Full Text] [Related]
23. Somatic mutations in thyroid nodular disease.
Krohn K; Paschke R
Mol Genet Metab; 2002 Mar; 75(3):202-8. PubMed ID: 11914031
[TBL] [Abstract][Full Text] [Related]
24. Constitutively activating TSH receptor mutations as the cause of toxic thyroid adenoma, multinodular toxic goiter and autosomal dominant non autoimmune hyperthyroidism.
Paschke R
Exp Clin Endocrinol Diabetes; 1996; 104 Suppl 4():129-32. PubMed ID: 8981020
[TBL] [Abstract][Full Text] [Related]
25. Beta-arrestin signaling and regulation of transcription.
Ma L; Pei G
J Cell Sci; 2007 Jan; 120(Pt 2):213-8. PubMed ID: 17215450
[TBL] [Abstract][Full Text] [Related]
26. β-Arrestin 1 in Thyrotropin Receptor Signaling in Bone: Studies in Osteoblast-Like Cells.
Boutin A; Gershengorn MC; Neumann S
Front Endocrinol (Lausanne); 2020; 11():312. PubMed ID: 32508750
[TBL] [Abstract][Full Text] [Related]
[Previous] [New Search]
